The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 12, 2024

Filed:

Dec. 02, 2016
Applicant:

Juno Therapeutics, Inc., Seattle, WA (US);

Inventors:

Lucas James Thompson, Seattle, WA (US);

Robert F. Dubose, Bellevue, WA (US);

Archana Brahmandam, Seattle, WA (US);

Assignee:

Juno Therapeutics, Inc., Seattle, WA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 35/17 (2015.01); C07K 14/705 (2006.01); C07K 14/74 (2006.01); C12N 5/0783 (2010.01); C12N 5/10 (2006.01); A61K 35/66 (2015.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01); A61P 37/00 (2006.01); C07K 7/06 (2006.01); C07K 9/00 (2006.01); C07K 16/28 (2006.01); C12N 15/62 (2006.01); C12N 15/86 (2006.01);
U.S. Cl.
CPC ...
C07K 14/70539 (2013.01); A61K 35/17 (2013.01); C07K 14/705 (2013.01); A61K 35/66 (2013.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01); A61P 37/00 (2018.01); C07K 7/06 (2013.01); C07K 9/00 (2013.01); C07K 16/2812 (2013.01); C07K 16/2815 (2013.01); C07K 16/2818 (2013.01); C07K 2317/56 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01); C07K 2319/033 (2013.01); C12N 5/10 (2013.01); C12N 15/62 (2013.01); C12N 15/86 (2013.01);
Abstract

Provided are chimeric receptors for engineering cells for adoptive therapy, including T cells, and the genetically engineered cells. In some embodiments, the chimeric receptors, such as chimeric antigen receptors (CARs) are modified in a junction region by one or more amino acid modifications such that peptide fragments of such region exhibit a lower binding affinity for a human leukocyte antigen (HLA) and/or the region exhibits reduced immunogenicity, including following administration to a subject. In some aspects, also provided are methods and compositions for engineering and producing cells expressing such chimeric receptors, compositions containing the cells, and method for their administration to subjects. In some embodiments, features of the chimeric receptors and engineered cells containing the chimeric receptors result in methods that provide for increased or improved activity, efficacy and/or persistence.


Find Patent Forward Citations

Loading…